

a 2013 0073

The invention provides a new crystal form VII of agomelatine, a preparation method and use thereof, and a pharmaceutical composition containing the same.

The new crystal form has a good purity, a stable crystal form and good reproducibility. It is superior to most previously reported crystal forms in terms of stability and purity. Therefore, the crystal form VII of the present invention has an advantage in terms of preparation. The preparation method, according to the invention, comprises dissolution of agomelatine compounds in acetic acid, to which acetate is then added, followed by the addition of water dropwise to this reaction mixture, which is then agitated at a temperature of 17-23°C in order to bring about crystallization, with the crystals then being separated from the solution.

Claims: 13

Fig.: 4